`SECURITIES AND EXCHANGE COMMISSION
450 5TH  STREET NW
WASHINGTON, D. C. 20549

---------------------------------

         FORM 10-KSB/A Annual Report Pursuant to Section 13 or 15 (d ) of
the Securities Exchange Act of 1934



FOR THE FISCAL YEAR ENDED DECEMBER 31, 2000   COMMISSION FILE NUMBER -  0-31437

NEUROGENESIS, INC.
(EXACT NAME OF COMPANY AS SPECIFIED IN IT'S CHARTER)



       DELAWARE                                            76-0320137
_______________________________              _______________________________
(State or other jurisdiction of            ( IRS Employer Identification Number)
  incorporation or organization)

2045 SPACE PARK DRIVE, SUITE 132, HOUSTON, TEXAS  77058
(Address of Principal Executive Offices )


Company's telephone number including area code: (281) 333-0177

SECURITIES REGISTERED PURSUANT TO SECTION 12 (B) OF THE ACT:
None

SECURITIES REGISTERED PURSUANT TO SECTION 12 (G) OF THE ACT:
($0.025)  Par Value Common Stock

Indicate by check mark whether the Company : (1) has filed all reports
required to be filed  by Section 13 or 15 (d) of the Securities Exchange Act
of 1934 during the preceding 12 months ( or such shorter period that the
Company was required to file such reports ) ; and (2) has been subject to
such filing requirements for the past ninety ( 90) days.

Yes  ( X )  No  (  )
The Issuer's revenues for the year ended December 31, 2000 were $

As of December 31, 2000 there were 2,046,587 shares of  ($0.025) par value
Common Stock ( the Company's only class of voting  stock) outstanding .There
are 25,000,000 shares of Common Stock, par value $0.025, and 500,000 shares of
Preferred Stock authorized. The aggregate market value of the Company on
December 31, 2000 ( based upon the mean of the closing bid and asked price )
held by nonaffiliates of the Company, was $ 266,086


DOCUMENTS INCORPORATED BY REFERENCE
None




FORM 10-KSB/A

NEUROGENESIS, INC.

TABLE OF CONTENTS


PART I
Item    1.        Description of Business
Item    2.        Description of Property
Item    3.        Legal Proceedings
Item    4.        Submission of Matters to a Vote of Security Holders

PART II
Item    5.        Market for Common Equity and Related Stockholder Matters
Item    6.        Management's Discussion and Analysis of Plan or Operations
Item    7.        Financial Statements
Item    8.        Changes in and Disagreements with Accountants on
                   Accounting and Financial Disclosure

PART III
Item    9.        Directors, Executive Officers, Promoters and Control
                   Persons: Compliance with Section 16(a) of the Exchange Act
Item   10.        Executive Compensation
Item   11.        Security Ownership of Certain Beneficial Owners and
                   Management
Item   12.        Certain Relationships and Related Transactions
Item   13.        Exhibits and Reports on Form 8K


SIGNATURES


PART I


ITEM   1. DESCRIPTION OF BUSINESS

       THE COMPANY

NeuroGenesis, Inc.  ( the "Company" ) was incorporated in Utah on August 6,
1984 as Cozmal Technology, Inc. as an organization to find and promote new
technology. On January 27, 1989 the name was changed to NeuroGenesis, Inc. At that
time a definitive reorganization agreement ( the " Reorganization Agreement" )
was completed between the Company and Matrix Technologies, Inc. , a Texas corporation.
Matrix Technologies, Inc. ( " Matrix " ) was incorporated  November 13, 1984
to acquire the patentable work of Doctor Kenneth E. Blum, PhD, relating to
nutritional supplementation and the efficient functioning of the hypothalamus
and the hippo campus of the human brain and to promote that work. On July 16,
1995 " Matrix " amended the Articles of Incorporation changing the authorized
shares from ten thousand (10,000) to one million five hundred thousand (
1,500, 000 ) in order that funding could be accomplished to promote the
completed Blum formulations. The initial funding was a $250,000 loan from
Lloyd's Bank. The loan was guaranteed by Albert H. Bieser, President of "
Matrix ". In exchange for the loan guarantee Mr. Bieser received one common
share for each dollar of loan guarantee. In accordance with the conditions of
the " Reorganization Agreement " the Company conveyed four million two hundred
thousand (4,200,000) shares of it's Common Stock to the shareholders of "
Matrix " in exchange for 100 % of the issued and outstanding shares of "
Matrix ". The Company also agreed to honor certain stock purchase options that
had been previously granted to certain persons by " Matrix " which in the
aggregate entitled the holders thereof to purchase up to two million
ninety-eight thousand (2,098,000) Shares of the Company's Common Stock at a
price of one dollar ($1.00) per share at any time prior to December 1, 1993.
These options expired without being exercised by the holders. The Company then
entered a market research program and found that the best method to sell the
product at that particular time was to market direct to physicians and hospitals.
The combined  research of marketing and product led to a three hundred thousand
dollar ($300,000) financing through the acquisition of Cozmal Technologies, Inc.,
a small public compamny whose situation at that time made it ideal for a reverse
merger. As a result of this, the shareholders of Cozmal retained ten percent of the
outstanding shares and the Matrix shareholders received ninety percent of the
outstanding shares of Cozmal. Following the reorganization Matrix owned no
assets and possessed no liabilities and was kept as a wholly owned inoperative
subsidiary of the Company. The " Reorganization Agreement " also called for
the resignation of the Company's Board of Directors and the appointment of a
new Board of Directors consisting of Albert H. Bieser, Gary E. Bell, Michael
C. Trachtenberg, F. Lynn Estep and R. Bradford Perry. On April 19, 1989 the
Company was merged into NeuroGenesis, Inc. , a Delaware Corporation with an
authorized capital of Fifteen Million ( 15,000,000 )  at a par value of
$0.001 per share. NeuroGenesis, Inc. a Utah corporation was dissolved after
the merger

On October 17, 1990 Robert Baldwin replaced Albert H. Bieser as CEO and Board
Chairman.A series of management changes then occurred during which time sales
decreased from a high of $129,00 in October 1989 to a monthly low of
approximately $10,000 in September 1993 due to an FDA ban on Tryptophan,a
significant component of the only product of the Company at that time. A few
months later the Company was taken over by the financial interest of the
Company.

     In September 1993 Lloyd's Bank had not received repayment of their 1985
loan which had now totaled $475,000 in principal and interest and was in
default. The Bank agreed to defer payment for eighteen months in exchange
$75,000 immediately and regularly scheduled monthly payments after the
eighteen month period. Albert H. Bieser  provided the immediate cash payment
of $75,000 and guaranteed the loan balance  in exchange for the Company's
agreement to award the intellectual rights ( patents, trademarks, etc to
Albert H. Bieser in the event the Company defaulted on the loan. By March 10'
1995 no payments on the loan had been made to Lloyd's Bank. The loan was
called and Albert H. Bieser's assets securing the loan were acquired by the
Bank. On April 6, 1995 the Company's Board of Directors ordered the transfer
of the intellectual properties to Albert H. Bieser who in turn gave royalty
free license to the Company as long as he remained CEO or President and
Chairman of the Board. In the event of his resigning this office, he, his
heirs or assigns would receive a royalty equivalent to one cent ($0.01) per
capsule.

     At this time Matrix Technologies, Inc. was dissolved.

On April 5, 1995 the following new directors were elected ; Albert H. Bieser,
chairman, Karen Coady and David Bishop.

On February 11, 1998 the Company acquired 100 % 0f the outstanding shares of Natural
Neuro Nutrition, Inc.,( 3NI), a Texas Corporation, for Three Hundred
ninety-seven Thousand  Nine Hundred Sixty ( 397,960 ) shares of the Company's
Common Stock and Neuro Health Products, a sole proprietorship, for One Hundred
Two Thousand and Forty (102,040) shares of the Company's Common Stock.  3NI
was an operating company selling similar  products under license from
Neurogenesis, Inc. which had facilities, marketing, management teams,
customers, and product fulfillment capability. NHP was a small network
marketing firm which sold products similar to those of the Company.

When Insurance Companies and the Federal Government stopped " third party "
payment for nutritional products used in the treatment of alcohol and drug
addiction, the Company determined to market directly to the end-user and
developed NHP as a network marketing company. A network marketing company
differs from a multi-level company in that the required sales volume is
typically only a one month supply of inventory to the individual distributor
as opposed to monthly sales requirements.-


( B ) DESCRIPTION OF THE BUSINESS

Alcoholism and Cocaine Addition have a devastating nutritional effect on a
number of different neurotransmitter systems within the human body. Therefore
the Company believes that an effective nutritional supplement for recovering
alcoholics and addicts must focus on substantially all of the more common
nutritional deficiencies . NEURECOVER-DA and NEURECOVER-SA, the Company's
principal products have been specifically formulated to provide the raw
materials that are used by the human body to repair damaged neurotransmitter
systems. In the opinion of the Company's scientist, this approach  allows the
natural mechanisms of the body to select the specific nutrients it needs and
discard the nutrients that are not needed.

These two products have been carefully formulated to provide the specific
amino acids that are essential to the restoration  of proper brain chemistry
in recovering alcoholics and cocaine addicts by providing a ready supply of
raw amino acid  that can be used by the brain to synthesize necessary
neurotransmitters. While the ingredients have no direct psychological effect
on a recovering alcoholic or cocaine addict, NEURCOVER-DA and NEURECOVER-SA
have the ability to increase  dietary levels of the specific amino acids that
are that are used in the synthesis of essential neurotransmitters. These
formulations will not alter the base line ability of the body to synthesize
neurotransmitters. They will, however,  ensure an adequate supply of raw
materials in order that the brain's own neurotransmitter production systems
are able to operate efficiently.

     NEURECOVER-DA

The first product that was developed by the Company is NEURECOVER-DA, a
patented  amino acid formulation that has been marketed to over 1700 hospitals
and clinics from 1985 to the present time. Sales for the year 2000 totlaed
approximately  $66,240.

The active ingredients in NEURECOVER-DA  are:  DL- Phenylalanine, a naturally
occurring amino acid that is used by the body to synthesize dopamine and
norepinephrine and inhibit the action  of the enzymes that break down and
recycle enkephaline and endorphins; L-Tryptophan, a naturally occurring amino
acid that is used by the body to synthesize serotonin; L-Glutamine, a
naturally occurring amino acid that is used by the body to synthesize
Gamma-Amino Butyric acid (GABA); and Vitamin B6, a natural vitamin which aids
the absorption of the amino acids by the digestive system  and the synthesis
of amino acids in the brain.

The primary markets for NEURECOVER-DA are people who are addicted to alcohol,
drugs, carbohydrate abuse, those who suffer from Attention Deficit Disorder or
hyperactivity disorder and those who suffer from the effects of excessive
pyschological stressors

Alcoholism counselors who have used NEURECOVER-DA with their patients report
reduced levels of anger, urgency, irritation and compulsion coupled with
increased levels of cooperation and earlier treatment response. In general,
NEURECOVER-DA has been well received by the alcohol treatment professionals
who have used the product with their patients and it is steadily gaining
acceptance as a useful nutritional adjunct to traditional alcohol treatment
programs.

Currently the product is marketed through distributors to the end-user. As of
this date the only advertising method in use by the Company is " word of
mouth" and distributor direct contact.

NEURECOVER-SA
The Company's second product has achieved similar results with persons who are
recovering from cocaine addiction. Because of the unique cocaine addicts
,however, the formulation of  NEURECOVER-SA is more complex. In addition to
the amino acids in the formulation, NEURECOVER-SA includes L-Tyrosine, an
amino acid which is essential for the production of both dopamine and
norepinephrine. Further,  the formulation includes a number of vitamins and
minerals that are not present in NEURECOVER-DA.

In general, Neurecover-SA has been well received by the cocaine treatment
professionals who have used the product with their patients. Like
NEURECOVER-DA, NEURECOVER-SA is steadily gaining acceptance as  a useful
nutritional adjunct to traditional cocaine treatment programs.

As this is a patented product, it only has direct competition, those clinics
which do not use the product.

BeCALM'd
This product is similar in composition to SAAVE, which has been tested and
proven in scientifically  supervised clinical trials to greatly reduce the
long and short term dilatory effects of stress and many of the symptoms of
Hyperactivity Disorders and Attention Deficit Disorders.

All of the ingredients in the Company's products are made from items on the
GRAS list of vitamins, minerals, amino acids, etc. Curative claims are not
made for the products, only that they are useful adjuncts to therapy which has
been accepted by the general scientific community.


( C ) Patents and Trademarks

     The Company operates under three patents and one registered trademark.

(1)      Patent Number 4,761,429 ENKEPHALINASE and ENDORPHINASE INHIBITORS AS
ANTI-CRAVING COMPOSITIONS.

     This patent was adjudicated in federal court as follows: That the 429
Patent covers any preparation using D- phenylalanine or ant effective
combination of the following ingredients: D-phenylalanine; DL-phenylalanine;
D- leucine; DL-leucine; L-tryptophan ( or a substitute ) and hydrocinnamic
acid in the treatment of or prevention of alcoholism and/or the treatment or
prevention of cravings for alcohol. Cocaine and other narcorics. The 429
Patent also covers any preparation containing such ingredients used for the
treatment of cravings for excessive amounts of foods containing carbohydrates;
sress-induced damage; attention deficit hyperactivity disorders and all other
disorders that are related to neurotransmitter insufficiencies".

(2) Patent Number 5,189,064 TREATMENT OF COCAINE ADDICTION
          This Patent was adjudicated in Federal Court as follows: " That the
064 Patent covers among it's other claims, a composition used for treatment of
cocaine and other narcotic addictions and/or to reduce cravings for cocaine
other narcotics, cosisting of: (a) hydrocinnimic acid, any D-formmono amino
acid, D-phenylalanine, and/or DL-phenylalanine; and (b) L-glutam,ic acid,
L-glutamate and/or L-glutamine and/or L-tryptophan ( or a substitute). The 064
Patent also covers any preparation containing such ingredients used for the
treatment or prevention of cravings for excessive amounts of foods containing
carbohydrates; strees induced organ damage; and attention
deficit/hyperactivity disorders and all other disorders that are related to
neurotransmitter insufficiencies".

(3)      Patent Number 5,922,361 FOLIC ACID ENRICHED DIATARY SUPPLEMENT
COMPOSITIONS FOR SELF REGULATING STRESS-REDUCTION

     This Patent has not been adjudicated. It claims the uses of the 429 and
064 patents and teaches that the formulae in them can be improved through the
use addition of Folic Acid.



     ( D ) FEDERAL REGULATION
             In general the FDA " protects" consumers in two ways:  (1)
Anything sold for use by the American public must be safe for consumption and
(2) Any curative claims must be approved by the FDA before such claims are
made. Both of these "protections' are applied to products, regardless of form,
that are used for medicinal purposes. However , such products fall in two classes:
(a) Those made from manmade molecules and (b) Those formulated from natural
nutrients found on the FDA's  GRAS ( Generally Regarded As Safe) list Thus
anyone may sell anything processed in an FDA approved  facility by an approved
method, provided there are no curative claims made for the product. If any
curative claims are made, the product falls under regulation by the FDA. The
one exception to this is curative benefits which the " scientific community "
generally accepts as true. For example , Vitamin C or foods containing Vitamin
C are generally regarded as helpful to persons having a cold In this case the
Vitamin C manufacturer may say it useful but cannot claim it cures the cold.

     All of the ingredients in the Company's products are made from items on
the GRAS list of vitamins, minerals, amino acids, etc. Curative claims are not
made for the products , only that they are useful adjuncts to therapy which
has been accepted by the general scientific community.


(D) MARKETING
As indicated under " Business Development" the Company markets through it's
two wholly owned subsidiaries 3NI and  NHP. Most of the sales are generated
through direct sales, advertising and referral.


(E)      RETURNS AND WARRANTIES
Individual consumers are sold on a thirty day return basis with the customer
paying the freight. Hospitals and similar institutions are sold on a ninety
day return basis with the customer paying freight and a thirty percent
restocking fee.


(F)      EMPLOYEES
The Company employs on a regular basis four to five employees. However most of
the work is contracted out to unaffiliated companies and includes product
manufacturing, bottling, labeling and much of it's research.


(G)      CUSTOMERS
     At the present time the Company has over twenty-eight hundred customers
which are serviced through approximately two hundred independent dealers. In
addition to this marketing network the Company sells to approximately ten
hospitals or similar institutions on a direct basis.

(H)  COMPETITION
     The Company's products are patented and these patents have been twice
adjudicated  successfully therefore the Company feels confident that further
judicial testing will produce the same results. Thus there is no direct
competition. However there are indirect competitors for all the products;

(A) NeuRecovery-DA has few current competitors. Several drugs have been tried
in the past but in general they were shown to be addictive or
ineffectual. A perennial drug called Anabuse re-emerges every three or four
years. If a person has taken it and then drinks alcohol, he or she becomes
violently ill and in a few cases have been known to have a stroke as a result
of the dosage. Another newer one is from Europe. It is called  Acomprosate and
has been found useful for thirty days in thirty percent of the cases which
have thirty days of sobriety.

(B) NeuRecovery-SA has proved to be very useful as an adjunct to therapy n
recovery from the abuse of stimulants such as
cocaine and the amphetamines. The drugs used most commonly in the treatment of
such addictions are  Disipramine, Bromcriptine and Amantadine.

(C)  beCalm'd was originally formulated to diminish the dilatory effects of
stress. In this use it's competition was generally books on stress management.
To this date no other competition has general use. beCalm'd was later found to
be very helpful in the treatment of  attention deficit and hyperactivity
disorders. It's principal competition is Ritalin and several drugs of the
amphetamine type. The mechanism of action of these are unknown and their side
effects are severe.  Never-the-less, the world's second largest pharmaceutical
company, Ciba Geigy, the makers of Ritalin have stated that two thirds of
their revenues come from the sale of Ritalin. Studies have shown that beCalm'd,
the mechanism of action of which is well known and accepted, is more
effective than Ritalin in 62.5% of ADHD cases.

ITEM 2.      DESCRIPTION OF PROPERTY

NeuroGenesis, Inc.'s principal office is located at 2045 Space City Drive,
Suite 132, Nassau Bay, Texas 77058 and currently occupies 2000 square feet of
office and storage area.. The property is leased from an unaffiliated third
party for a monthly rental of  Seventeen hundred and thirty-four dollars
including all utilities and use of common areas. The current lease expires on
May 1, 2001, however management ascertains that there is very small likelihood
that the Company would not be able to renew the lease at about the same rate
as there numerous vacancies in the immediate area.

ITEM     3     LEGAL PROCEEDINGS


     None

ITEM     4     SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS


     None


PART II

ITEM     5     MARKET FOR COMMON EQUITY  AND RELATED STOCKHOLDER  MATTERS

     The table below sets forth the high and low bid prices as reported by the
National Quotation Bureau for the periods indicated. Such over- the- counter
market quotations reflect inter-dealer prices without retail mark-up,
mark-down or commissions and may not necessarily represent actual
transactions.

     FISCAL YEAR ENDING DECEMBER 31, 1999          LOW          HIGH

          First Quarter                           $0.25          $0.25
          Second Quarter                          $0.25          $0.25
          Third Quarter                           $0.25          $0.3125
          Fourth Quarter                          $0.51          $0.51

     FISCAL YEAR ENDING DECEMBER 31, 2000

          First Quarter                           $0.51          $1.03125
          Second Quarter                          $0.01          $0.01
          Third Quarter                           $0.06125       $0.06125
          Fourth Quarter                          $0.06125       $0.06125



     As of December 31, 2000 the Company  had approximately 171 shareholders
of record. The Company has never paid any cash dividends and has no plans to
pay  any cash dividends in the foreseeable future.


ITEM      6.     MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION LIQUIDITY

     The Company had total liabilities of $314,259 at December 31, 2000
compared to $322,612 at December 31, 1999 and a working capital deficit of
at December 31, 2000 compared to a deficit as of December 31, 1999. This increase
in working capital is attributable to 149.2% increase in sales for 2000 as
compared to 1999. The Company expects that cash requirements for operations for the
next fiscal year will be provided by an increase in sales for the year-ending
December 31, 2001 and sales tools currently being installed by means of software
integrating with the Company Website. However, there can be no assurance that
these activities will, in fact, provide the necessary working capital for operations.


YEAR ENDED DECEMBER 31, 2000 COMPARED WITH 1999

The Company sales of $413,030 generating a gross profit of $303,545 for year
ended December 31, 2000 as compared to sales of  $276,815 and a gross profit
of $194,795 for the year ended December 31, 1999. Expenses ( including
interest ) were $298,013 for the year 2000 compared to $504,425 for the year
1999. This dramatic reduction of expenses was in part due to a one time law
firm fee of $326,726 in successful defense of the Company's Patent in 1999.
The Company plans to continue to maintain  expenses at the lowest possible
level until sales volume generates an acceptable level of gross profit.
However, the Company expects that future operations will be funded by sales
increases for the ensuing year.

YEAR ENDED DECEMBER 31, 1999 COMPARED WITH 1998

The Company had $276,815 1n sales and a gross profit of $194,795 for the year
ended December 31, 1999 as compared to sales of  $141,038 and a gross profit
of  $42,624 for the year ended December 31, 1998. Expenses ( including
interest ) were $504, 425 for 1999 compared to $116,058 for 1998.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: The information contained in the preceding paragraphs is forward looking
and involves risks and uncertainties that could significantly impact expected
results. While it is impossible to itemize the many factors and specific
events that would affect the outlook of any company, the Company's outlook for
fiscal 2001is predominantly based on it's interpretation of  what it considers
key economic assumptions.


ITEM     7.      FINANCIAL STATEMENTS

     The information required by this item is included in a separate section
of this Annual Report beginning after Part IV.


NEUROGENESIS, INC.

Comparative Financial Statements

December 31, 2000 and 1999




Clyde Bailey, P.C.
Certified Public Accountant
10924 Vance Jackson #404
San Antonio, Texas 78230

CLYDE BAILEY P.C.
______________________________________________________________________________
Certified Public Accountant
10924 Vance Jackson  #404
San Antonio, Texas 78230
(210) 699-1287(ofc.)
(888) 699-1287  ̈ (210) 691-2911 (fax)
Member:
American Institute of CPA's
Texas Society of CPA's


Board of Directors
NeuroGenesis, Inc.
Houston, Texas

REPORT OF INDEPENDENT PUBLIC ACCOUNTANT

We have audited the accompanying balance sheet of NeuroGenesis, Inc. (Company)
as of December 31, 2000 and 1999, and the related statements of operations,
changes in stockholders' equity, and cash flows for the years then ended.
These financial statements are the responsibility of the Board of Directors.
Our responsibility is to express an opinion on these financial statements
based on the results of the audit.

We conducted our audit in accordance with generally accepted auditing
standards.  Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining,  on a test basis, evidence
supporting the amounts and disclosures in the financial statements.  An audit
also includes assessing the accounting principles used and significant overall
financial statement presentation.  We believe that our audit results provide a
reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial condition of NeuroGenesis, Inc. at
December 31, 2000 and 1999, the results of its operations and its cash flows
for the years then ended, in conformity with generally accepted accounting
principles, except with respect to net operating loss carryforwards available
to offset future taxable income, as described in Note 7 of these financial
statements.



Clyde Bailey
Certified Public Accountant

February 17, 2001






1



NeuroGenesis, Inc.
Balance Sheets
As of December 31, 2000 and 1999


A S S E T S

                                                       2000          1999
Current Assets:
     Cash and cash equivalent                           $51,325       $31,231
     Accounts receivable, net of allowance               17,059        20,327
          for doubtful accounts
     Inventories                                         29,173        44,544
     Prepaid Expenses                                    39,412        33,042


               Total Current Assets                     136,969       129,144

Fixed Assets:
     Furniture and office equipment,                      6,954         9,798
          net of accumulated depreciation of
          $10,125 for 2000 and $ 10,655 for 1999
     Patents, net of accumulated amortization            12,529        10,018
          of $940 for 2000 and $392 for 1999

               Total Fixed Assets                        19,483        19,816


               Total Assets                            $156,452      $148,960



L I A B I L I T I E S    and   S T O C K H O L D E R S'    E Q U I T Y


                                                       2000          1999
Current Liabilities
     Accounts Payable                                   $16,411      $344,683
     Note Payable - Related Party                       165,018       155,959
     Loans from directors                               132,531       144,120

               Total Current Liabilities                313,960       644,762


Stockholders' Equity
     Preferred Stock, par value $.025 per share               -             -
          authorized 500,000 shares, no shares outstanding
     Common Stock,                                       50,090        43,769
          par value $.025 per share,
          authorized 25,000,000 shares;  2,003,588 and
          1,750,750 shares issued and outstanding
          at December 31, 2000 and 1999
     Additional Paid-In Capital                       2,167,767     1,780,938
     Accumulated Deficit                             (2,375,365)   (2,320,509)

               Total Stockholders' Equity              (157,508)     (495,802)

               Total Liabilities and Stockholders'
                Equity                                 $156,452      $148,960



NeuroGenesis, Inc.
Statement of Operations
For the Years Ended December 31, 2000 and 1999



                                                       2000          1999

     Sales, net of discounts                           $413,030      $276,815
     Cost of Sales                                      109,485        82,020

               Gross Profit                             303,545       194,795

     Legal and Professional Fees                       $      -       322,150
     Selling, general and administrative expenses       349,008       108,183

               Operating Income (Loss)                  (45,463)     (235,538)

     Other Income (Expense):
          Interest (expense)                             (9,393)       (8,828)
          Other Income (expense)                              -        (4,576)

               Other Income, net                         (9,393)      (13,404)

               Net Income (Loss)                       $(54,856)    $(248,942)

               Net Income (Loss) per share             $      -        $(0.18)

               Weighted average shares outstanding    2,003,588     1,750,750




NeuroGenesis, Inc.
Statement of Changes in Stockholders' Equity
For the Years Ended December 31, 2000 and 1999


                                                              Additional                  Total
                                        Common Stock          Paid-In       Accumulated   Stockholders'
                                   Shares          Amount     Capital       Deficit       Equity


Balance December 31, 1998           1,750,750      43,769     1,780,938    (2,071,567)     (246,860)

     Net Loss, December 31, 1999            -           -             -      (248,942)     (248,942)

Balance December 31, 1999           1,750,750      43,769     1,780,938    (2,320,509)     (495,802)

     Stock Issued                     382,838       9,571       373,267             -       382,838

     Stock Cancelled                 (140,000)     (3,500)        3,500             -             -

     Stock issued for services         10,000         250        10,062             -        10,312

     Net Loss, December 31, 2000            -           -             -       (54,856)      (54,856)

Balance December 31, 2000           2,003,588     $50,090    $2,167,767   $(2,375,365)    $(157,508)




NeuroGenesis, Inc.
Statement of Cash Flows
For the Years Ended December 31, 2000 and 1999


                                                                 2000               1999
     Cash Flows from Operating Activities:

          Net Income (Loss)                                     $(54,856)           $(248,942)

          Operating expenses not requiring use of cash:
               Amortization expense                                  548                  392
               Depreciation expense                                3,281                2,790
               Shares issued for services                        393,150                    -

          Net (increase) decrease in operating assets and
           liabilities                                          (330,445)             265,193

     Net Cash Provided by Operating Activities                    11,678               19,433

     Cash Flows from Investing Activities:

          Purchase of property and equipment                      (3,607)             (13,631)

     Net Cash Provided by  Investing Activities                   (3,607)             (13,631)

     Cash Flows from Financing Activities:

          Increase in notes payable                                9,358                8,828
          Payment of notes payable                                     -                    -

     Net Cash Provided by Financing Activities                     9,358                8,828

     Net Increase (Decrease) in Cash                               17,429              14,630

     Cash -Beginning of year                                       31,231              16,601

     Cash -End of year                                            $48,660             $31,231


     Supplementary Disclosure:
               Cash Paid for Interest                               9,393               8,828
               Cash Paid for Taxes

     Non-cash transactions:
          (See Statement of Stockholders' Equity)
               Shares Issued for Services                          20,312             382,838
               Shares Issued for Assets                                 0                   0




NEUROGENESIS, INC.
Notes to Financial Statements

Note 1- ORGANIZATION

NeuroGenesis, Inc. (the "Company") is a Delaware Corporation and is the
successor to the business operations of Matrix Technologies, Inc., a Texas
Corporation, which was incorporated in November 1984 for the purpose of
completing the development of a series of products to be used as adjuncts to
therapy by the substance-abuse treatment community. The company has a total of
50,000,000 authorized common shares with a par value of $.025 per share and
with 2,002,588 common shares issued and outstanding as of December 31, 2000.
The Company has a total of 5000,000 authorized shares of preferred stock with
a par value of $.025 and no shares are outstanding.

In November of 1989, one of the components of the main product, 1-tryptophan,
was banned by the FDA.  This required destruction of product inventory and
resulted in a substantial decline in sales over the next few years.  During
1991 the majority of directors resigned and new directors were elected.  By
1993, sales had fallen to less than 20% of the 1990 levels.  In 1991 one of
the Company's  original Founders formed a new company,  Natural Neuro
Nutrition, Inc. (3NI), to develop new research and pursue similar goals of the
original company.

NeuroGenesis, Inc. unsuccessfully pursued legal action against the new
company, 3NI, which was settled in August  of 1993 and resulted in the Company
giving 3NI a royalty free license and reinstating the founder of 3NI on the
Board of Directors of NeuroGenesis, Inc.

After settlement of the litigation in 1993, the Founder began reorganization
of NeuroGenesis  Inc. The Company, from an operational point of view, was
basically inactive until February 1998.  At that time, the Company acquired
3NI and a network marketing company, Nuero Health Products, in exchange for
500,000 shares of common stock valued at approximately $125,062..

Note 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Inventory
Inventories are stated at the lower cost or market.  Cost is determined using
an average cost method.

Property and Equipment
Property, and  equipment are reported at a cost.  Repairs and maintenance
costs are charged to operations when incurred.

Depreciation
Depreciation is calculated using the straight-line method, based on the
estimated useful life of the respective asset, which ranges between five years
and ten years.  Depreciation expense for 2000 and 1999 was $3,281 and $2,790
respectively.





7
NEUROGENESIS, INC.
Notes to Financial Statements
Stock Based Compensation
Statement of Financial Accounting Standards No. 123, "Accounting for Stock
Based Compensation" established a fair value method for accounting for
stock-based compensation plans either through recognition or disclosure.  The
Company did not adopt the fair value based method but instead discloses the
effects of the calculation required by the statement

Accounting Method

The Company's financial statements are prepared using the accrual method of
accounting. Revenues are recognized when earned and expenses when incurred.
Fixed assets are stated at cost. Depreciation and amortization using the
straight-line method for financial reporting purposes and accelerated methods
for income tax purposes.

Revenues are recognized in the period in which they occur.  Revenues are
recognized from sales of products when they are shipped. Revenue and expenses
are accrued at the end of the accounting periods for proper accounting in
order to comply with generally accepted accounting procedures.

Summary of Recent Accounting Pronouncements

SFAS 129
Statement of Financial Accounting Standards No. 129, Disclosure of Information
about Capital Structure ("SFAS 129"), effective for periods ending after
December 15, 1997, establishes standards for disclosing information about an
entity's capital structure. SFAS 129 requires disclosure of the pertinent
rights and privileges of various securities outstanding (stock, options,
warrants, preferred stock, debt and participating rights) including dividend
and liquidation preferences, participant rights, call prices and dates,
conversion or exercise prices and redemption requirements. Adoption of SFAS
129 has had no effect on the Company as it currently discloses the information
specified.

SFAS 130
In June 1997, the Financial Accounting Standards Board issued two new
disclosure standards. Results of operations and financial position are
unaffected by implementation of these new standard Statement of Financial
Accounting Standards (SFAS) 130, "Reporting Comprehensive Income", establishes
standards for reporting and display of comprehensive income, its components
and accumulated balances. Comprehensive income is defined to include all
changes in equity except those resulting from investments by owners and
distributions to owners. Among other disclosures, SFAS 130 requires that all
items that are required to be recognized under current accounting standards as
components of comprehensive income be reported in a financial statement that
is displayed with the same prominence as other financial statements.

SFAS 131
SFAS 131, "Disclosure about Segments of a Business Enterprise", establishes
standards for the way that public enterprises report information about
operating segments in annual financial statements and requires reporting of
selected information about operating segments in interim financial statements
issued to the public. It also establishes standards for disclosures regarding


8

NEUROGENESIS, INC.
Notes to Financial Statements


Summary of Recent Accounting Pronouncements (continued)
products and services, geographic areas and major customers. SFAS 131 defines
operating segments as components of an enterprise about which separate
financial information is available that is evaluated regularly by the chief
operating decision maker in deciding how to allocate resources and in
assessing performance. This accounting pronouncement has had no effect on the
Company's financial statements for the periods presented.

SFAS 132
Statement of Financial Accounting Standards (SFAS) 132, "Employers' Disclosure
about Pensions and Other Postretirement Benefits," revises standards for
disclosures regarding pensions and other postretirement benefits. It also
requires additional information on changes in the benefit obligations and fair
values of plan assets that will facilitate financial analysis. This statement
does not change the measurement or recognition of the pension and other
postretirement plans. The financial statements are unaffected by
implementation of this new standard.
SFAS 133
Statement of Financial Accounting Standards (SFAS) 133, "Accounting for
Derivative Instruments and Hedging Activities," establishes accounting and
reporting standards for derivative instruments, including certain derivative
instruments embedded in other contracts, (collectively referred to as
derivatives) and for hedging activities. It requires that an entity recognize
all derivatives as either assets or liabilities in the statement of financial
position and measure those instruments at fair value. If certain conditions
are met, a derivative may be specifically designated as (a) a hedge of the
exposure to changes in the fair value of a recognized asset or liability or an
unrecognized firm commitment, (b) a hedge of the exposure to variable cash
flows of a forecasted transaction, or (c) a hedge of the foreign currency
exposure of a net investment in a foreign operation, an unrecognized firm
commitment, an available-for sale security, or a foreign-currency-denominated
forecasted transaction. Because the Company has no derivatives, this
accounting pronouncement has no effect on the Company's financial statements.

Note 3 - PATENTS AND ROYALTIES

The Company has developed three patents since 1984.  Registration of the first
two patents was assigned to a key stockholder and officer of the Company in
1995 to partially satisfy a debt obligation (See Note 6).  At the time of
transfer the patents were valued at $89,153.  A third patent was developed in
1999 at a cost of $10,410.  The third patent was split into two applications
by the Patent and Trademark Office (PTO).  The first of these was awarded in
1999 and the second is pending.  It is anticipated that these two patents will
be assigned to the company by the two inventors (both officers of the
Company), if and when the award by the PTO is complete.




9
NEUROGENESIS, INC.
Notes to Financial Statements

Note 3 - PATENTS AND ROYALTIES (continued)

An agreement exists between NeuroGenesis, Inc. and the key stockholder and
officer, which allows the Company to use the patents without paying royalties
as long as the stockholder remains an officer of the Company and receives
renumeration according to the compensation agreement outlined in Note 8.  No
compensation was paid to this officer, under the compensation agreement,
during 2000 and 1999.

The patent assignment and royalty agreement requires the Company to pay
royalties of $.01 for each capsule manufactured by the Company if the
conditions stated above are not met.  No royalty fees were paid to this
officer or accrued under this agreement during 2000 and 1999.

All legal fees associated with the development and protection of the patents
have been paid by the Company and all proceeds of the law suits have been
given to the Company even though the patents have been assigned to a key
officer and shareholder of the Company.  Total legal fees paid by
NeuroGenesis, Inc. related to these patents were $28,684 in 2000 and $28,684
in 1999 (See Notes 4 & 5).

All royalty income has been given  to the Company.  During 2000 and 1999,
NeuroGenesis, Inc. received royalty income of $3,317 and $3,197 related to the
patents assigned to the officer and stockholder.

Note 4-  PATENT INFRIGEMENT LITIGATION

The Company has been involved in extensive litigation developing and
protecting the first two patents.  In September 1998 the Company obtained a
judgment against a former officer and stockholder of NeuroGenesis, Inc., in
the amount of $7.2 million for patent, trademark and trade dress
infringement,  misrepresentation, conversion breach of contract and breach of
fiduciary duty. Although the Company prevailed,  the defendant died prior to
the settlement of the judgment. Settlement with the estate of the defendant
provided a $15,000 cash payment to NeuroGenesis, Inc. and conveyance of
product inventory and accounts receivable valued at $19,976.  The $15,000 cash
was paid to legal counsel according to terms of the contingency agreement and
for accrued legal expenses (See Note 5).

In September 1999 the Company obtained a permanent injunction and a $50,000
judgment against an ex-distributor of NeuroGenesis, Inc.  and his company for
patent, trademark and trade dress infringement, misrepresentation in
commercial advertisement, misappropriation of trade secret, business
defamation and product disparagement, libel and slander.

Legal counsel for NeuroGenesis, Inc. filed a suit against the defendant in
December, 1999 for refusal to abide by the September 1999 settlement award and
is vigorously pursuing this case since the defendant and his company continues
to violate the court ordered injunction.  The outcome of this litigation is
uncertain.  The Company's legal counsel has retained , in escrow, $30,000 of
the $50,000 received to pay for the future legal expenses.



10
NEUROGENESIS, INC.
Notes to Financial Statements


Note 5-  LEGAL REPRESENTATION AND STOCK OWNERSHIP

In March 1998, the Company entered into a contingency ownership agreement with
their legal counsel to perform legal services for NeuroGenesis, Inc. in
connection with all cases related to patent infringement.  The contingency
percentage is 40% of all amounts recovered after filing suit, and 45% upon
filing an appeal.  The contingency percentage increases to 50% for defending a
counterclaim filed by another party against the Company, or for bankruptcy
proceedings filed by a defendant during  representation, or for bankruptcy
proceedings filed by the Company during representation.

As additional compensation for representation, legal counsel is entitled to an
equity ownership interest in NeuroGenesis, Inc. equal to 10% of the total
issued and outstanding stock, on a fully diluted basis, at the conclusion of
representation, with an option to increase the ownership interest to 20%
within six months after concluding representation.  In January 2000, the
Company issued 322,150 shares of common stock to legal counsel, which
represents 20% of all shares at December 31, 1999 (See Note 9).

Note 6- NOTE PAYABLE
In March 1995 NeuroGenesis, Inc. had a $446,459 bank loan, which was
personally guaranteed by an officer and major stockholder.  The bank
exercised  the guarantee and collected the amount due from the individual
shareholder.  In consideration to the shareholder for satisfying the debt,
the Company issued shares of common stock valued at $165,878 and the balance
of $280,581 was issued as a demand note, which bears interest at a rate of
6.0% per annum.  In April 1995 the Company transferred ownership of two
patents, valued at $89,153 to the officer and stockholder to reduce the
balance due on the demand note.

During 1997 the Company applied $80,000 of royalty income against this
shareholders note balance and paid the shareholder an additional $5,000
against the note (See Note 3).  The remaining principal balance of $106,428
has been renewed annually with accrued interest.  Total accrued interest
payable at December 31, 2000 and 1999 was $165,316 and $155,959.  Interest
expense was $9,358 and $8,828 for 2000 and 1999 respectively.

In addition to this note the Company is indebted to the same officer and
stockholder for legal expenses paid in connection with the lawsuit filed by
NeuroGenesis, Inc. against 3NI, Lloyd's Bank, and the Company officer, which
was settled in 1993.  The amount owed is not evidenced by a note and is not
accruing interest.  The balance owed to the stockholder was $132,831 at
December 31, 2000 and $143,159 at December 31, 1999. The note included
$105,000 for the Company's legal fees and the balance for working capital.







11
NEUROGENESIS, INC.
Notes to Financial Statements

Note 7- INCOME TAXES
The Company has net operating loss carry forwards available to offset future
taxable income of $1,728,933 and $1,734,465 for 2000 and 1999, respectively.
Approximately $5,468 will expire in 2001, $54,000 in 2002, and $50,000 will
expire in 2003.  Approximately $400,000 will expire in 2005, $662,000 in
2006,  $104,000 in 2007, $1,013 in 2008, and the balance of $109,375 in 2009.
The Company's tax records for  1992-1994 are not available as of the date of
this report.  These records were not turned over the current management when
all other directors resigned in 1994 (See Note 1).  Management is in the
process of obtaining the tax records from the Internal Revenue Service.
Note 8- EMPLOYMENT AGREEMENTS

The Company has an agreement to pay certain directors and employees
compensation based on net cash flow available, up to specified limits.  The
Boards of Directors must approve any compensation above the limits.  During
2000 and 1999 no payments were made under this agreement.  Only one director,
who is employed by the Company, was paid for services during 2000 and 1999.
The amount of compensation paid was employment related and is not part of this
compensation plan.


Note 9 - OPERATING LEASES
The Company leases its corporate headquarters in Houston, Texas for office and
warehouse space. Currently the Company occupies approximately 2,300 square
feet and the monthly rent is $ 1,734 per month. The lease began in April 1999
and expires on March 31, 2002. At December 31, 2000, future minimum lease
payments under these operating lease are as follows:

2001                     $  20,808
2002                         5,202


Total rent expense for the fiscal year ended December 31, 2000 and 1999 were
$20,808 and $19,616.






11
NEUROGENESIS, INC.
Notes to Financial Statements

Note 10 - Common Stock

In January 2000, the Company canceled 140,000 shares of common stock held by
previous officer and stockholder, in accordance with the lawsuit, which was
awarded in September 1998 by judgement (See Note 4).

The Company also issued 322,150 or 20% of its outstanding stock to legal
counsel in accordance  with their compensation agreement (See Note 5).  The
value of this transaction is $322,150.

An additional 60,688 shares of common stock were also issued in January 2000
to two Company directors in lieu of compensation.  The value of this
transaction is $60,688 based on the stock price on the date of issuance.

The Company also issued 10,000 for service valued at $10,312.

Note 11- FOOD AND DRUG ADMINISTRATION REGULATIONS

The Company presently markets its products as nutritional products,  rather
than therapeutic products.  The potential exists whereby the Company would be
required to obtain approval from the Food and Drug Administration (FDA) to
market its products.  In addition,  many states have statutory authority to
regulate drugs and other nutritional products.  Therefore,  there is risk that
the Company's products may become subject to state and federal regulations,
and there is no guarantee that FDA approvals, if required would be granted.



















12








ITEM     8.     CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS

              None


ITEM     9.     DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
                COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT

(A)      IDENTIFICATION OF DIRECTORS AND EXECUTIVE OFFICERS
     At the Annual Meeting of the Company's  shareholders on July 29, 2000,
the shareholders elected the following directors of the Company:

     William Barrow
     Albert H. Bieser, Chairman
     Lary Dorrington
     Terry Neher


     At the Annual Meeting of the Board of Directors held on July 29, 2000,
the following officers were elected:

     Albert H. Bieser           President, Treasurer and CEO
     Lary Dorrington            Vice President and Secretary
     Barbara S. Bieser          Assistant Secretary/Treasurer

     In addition, at March 1, 2001,  Albert H. Bieser owns 908,724  Shares of
the Company's Common Stock, either directly or through entities controlled by
him and is deemed to be a control person. On July 29, 2000 Mr. Bieser was
elected Chairman, President, Treasurer and Chief Executive Officer.

     All Directors of the Company hold office until the next Annual Meeting of
the Shareholders and until their successors have been elected and qualified.
Vacancies in the Board of Directors are filled by the remaining members of the
Board until the next annual Meeting of the Shareholders. The Officers of the
Company are elected by the Board of Directors at it's first meeting after each
Annual Meeting of the Company Shareholders. and serve at the discretion of the
Board of Directors or until their earlier resignation or death.

(B)      BUSINESS EXPERIENCE

Albert H. Bieser is Chairman of the Board, President, Treasurer, Chief
Executive Officer, a principal stockholder and a founding member of the
Company. He holds Bachelor of Science Degrees in Business Administration (
1953 ) and Electrical Engineering (1959) from the University of Colorado. He
also holds a Master of Science Degree in Electrical Engineering from Southern
Methodist University (1963). Prior to 1984 , Mr. Bieser served as the
President of B. E.  Industries, Inc. a successful private company that
manufactured ship board satellite antenna aiming systems; President of General
Computer Systems, Inc. , a publicly held firm which  manufactured a
proprietary " key-disk-tape " data entry subsystem ; and as Managing Director
of Recognition Equipment-Europe, a computer related company     .

Lary A. Dorrington is the Vice President of Marketing, Secretary, Director and
a principal shareholder of the Company. He holds a Bachelor of Science Degree
in Biology and Chemistry ( 1979 ) and a Master of Science Degree in Management
( 1989 )  from the University of Houston. He served in retail corporate
management with  Joske's (department stores) in Houston, Texas until 1981. Mr.
Dorrington has been a professional educator for the past nineteen years. He is
Past President of the Clear Creek Educators Association of the National
Educators Association, a member of Phi Delta Kappa, The Association for
Supervision and Curriculum Development, The Texas Science Teachers
Association, The Texas Association of Secondary School Principals and the
National Association of Secondary School Principals.

Dr.Terry Neher, DDS, CCDS, CAC, is Chairman of the Company's Advisory Board
and a Director of the Corporation. Dr. Neher received his doctoral degree from
Creighton University in 1964 and his Substance Abuse certification from
Spokane Falls College in 1986. He is currently the Executive Director of  the
Chemical Dependency Training Coalition  and is a professor in the Spokane
Falls Substance Abuse Program.

Dr. Neher is well known in the substance abuse recovery industry. He has
done research in this field since 1970 and is recognized as a leader in the
field of the Medical Model of addiction. In 1992 Dr. Neher engaged in research
as to the relationship of Hypothalamus and Hippo Campus neurotransmitters to
the symptoms of attention deficit/hyperactivity disorders. His research lead
to the conclusion that there is a close correlation. He therefore conducted a
clinical research. He chose be'Calmed, a major product of the Company, as the
adjunct and the results showed that 62.5% of those who had been taking Ritalin
showed more improvement on be'Calmed. Subsequent trials and anecdotal evidence
has shown that percentage to be correct. His work has become the mainstay of
the Company.

     The Company believes that many of Dr. Neher's  current research projects
will lead to even further uses of the current products and also to entirely
new products produced by the Company.


William R. Barrow, Director, holds a Bachelor of Science Degree in Chemical
Engineering from the University of Texas at Austin. He has had twenty-five
years experience as an independent oil operator and has both drilled and
operated numerous shallow wells in South Texas, as well as, deeper wells in
Texas and Louisiana. Mr. Barrow sold his oil company in 1991 and formed
Seabrook Energy in 1993. Currently Mr. Barrow is President of Seabrook Energy
Corporation.

Barbara S. Bieser, Controller and assistant Secretary/Treasurer, graduated
from the University of Iowa with a Bachelor of Arts Degree.  Mrs. Bieser has
extensive administrative experience with such companies as New England Mutual
Life Insurance Company, Boston , Mass., Farmers Insurance Group, Guarantee
Reserve Life Insurance Company and BE Industries. Mrs. Bieser is the wife of
Albert H. Bieser.


     ITEM     10.     EXECUTIVE COMPENSATION

(A)      SUMMARY COMPENSATION TABLE
      No executive of the Company was paid more than $60,000 in cash during
the fiscal years  2000 or 1999. The only cash paid   to officers was $36,000
paid to Allene S. Snow, Vice President in 2000 and $36,000 in 1999.


(B)      OPTION AND LONG TERM COMPENSATION TABLE
      There have been no restricted stock awards, stock options, SARs,
LTIP pay outs or other forms of long term compensation paid to any officer or
director of the Company during the past three years nor or there any
non-expired options effective at the present time.



(C)      PENSION PLANS AND OTHER BENEFIT OR ACTUARIAL PLANS
     The Company has no annuity, pension or retirement plan  nor other plans
whose benefits are based on actuarial computations.



(D)     EMPLOYMENT CONTRACTS AND TERMINATION AGREEMENTS
     The Company has no employment contracts or termination agreements with
any officer, director or key employee.



(E)     DIRECTOR COMPENSATION
     The following Directors received compensation in the Year 2000 for their
services:

     Name                      Compensation

     William R. Barrow         5000 Shares of Unregistered Common Stock

     Terry Neher               5000 Shares of Unregistered Common Stock



(A)            COMPENSATION COMMITTEE REPORT

The Company's Compensation Committee consists of Albert H. Bieser and Lary
Dorrington, who have nothing to report.


(A)            STOCK PERFORMANCE CHART

     A graph comparing the Company's commutative total return to stockholders
in terms of stock price appreciation plus dividends during the previous five
years to a broad market index such as the S&P 500, has not been presented due
to the Company's  operating losses in recent years and the resulting lack of
any significant stock price appreciation or dividends.


(H)      INTERLOCKING RELATIONSHIP OF DIRECTORS

     None


ITEM      11.     SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth , as of  December 31, 2000,  the stock
ownership of each person known by the Company to be the beneficial owner of
five percent or more of the Company's Common Stock . Unless otherwise
indicated , each person has beneficial voting and investment power with
respect to the shares owned.


Name                   Title           Direct      Beneficial        Total
                                    Shares Owned     Shares   Beneficial
Shares
William R. Barrow     Director         25408           0             25408

Albert H. Bieser      President,      908724           0            908724
                      Director
Barbara S. Bieser     Assistant            0           0                 0
                      Secretary
Lary A. Dorrington    Vice President, 102041        3401            105442
                      Director
Terry Neher           Director        101039           0            101039

Allene S. Snow        None            102041        1160            103201



     ITEM     12.     CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

               None


(A)      COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT

     Section 16(a) of the Securities Exchange Act of 1934, as amended ( the "
Exchange Act" ),  requires the Company's Officers,  Directors and  persons
who
own more than ten percent of a registered class of the Company's equity
securities, to file reports of ownership and changes in ownership with the
Securities and Exchange Commission. Officers, Directors and greater than ten
percent stockholders are required by the Securities and Exchange Commission
regulations to furnish  the Company with copies of all Section 16(a) forms
they file.

     Management believes that during the period from November 1, 2000 through
March 31, 2001, all 16(a) filing requirements applicable to it's current
Officers, Directors and greater than ten percent beneficial owners were
complied with.



PART IV

ITEM 13. EXHIBITS AND REPORTS FILED ON FORM 8K

     None


SIGNATURES:


     In accordance with Section 13 or 15(d) of the Exchange Act, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned , thereunto duly authorized.

NEUROGENESIS, INC.


By: _______________________________________         Date
    _______________________________________

     Albert H. Bieser, President and Chief Executive Officer`